PFIZER INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Enbrel-Juvenile Idiopathic Arthritis (JIA) Use Results Survey [All-Case Surveillance]
Completed
- Conditions
- Juvenile Idiopathic Arthritis
- Interventions
- First Posted Date
- 2010-06-16
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 113
- Registration Number
- NCT01145352
- Locations
- 🇯🇵
Yokohama City University School of, Tokyo, Japan
A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2010-08-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT01143805
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
A Multiple Dose Study To Determine Safety, Tolerability, and Pharmacokinetics Of PF-04634817 In Healthy Adult Subjects
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT01140672
- Locations
- 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States
Study To Evaluate The Effect Of A Multiple Oral Dose Of PF-00232798 On QT Intervals In Healthy Subjects
- First Posted Date
- 2010-06-09
- Last Posted Date
- 2010-12-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT01140425
- Locations
- 🇸🇬
Pfizer Investigational Site, Singapore, Singapore
Open, Non Comparative Study Of Voriconazole In Slovak Patients With Very High Risk Of Developing An Invasive Fungal Infection
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2011-09-02
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 177
- Registration Number
- NCT01137292
CP-690,550 And Oral Contraception Drug-Drug Interaction Study
- First Posted Date
- 2010-06-04
- Last Posted Date
- 2010-08-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT01137708
- Locations
- 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium
A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease
Phase 2
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2013-05-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 285
- Registration Number
- NCT01135511
- Locations
- 🇰🇷
Pfizer Investigational Site, Seoul, Korea, Republic of
A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease
- First Posted Date
- 2010-05-28
- Last Posted Date
- 2018-10-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 11
- Registration Number
- NCT01132690
- Locations
- 🇵🇾
Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C), Barrio Sajonia Asunción, Paraguay
🇮🇱Shaare Zedek Medical Center, Jerusalem, Israel
🇿🇦Morningside Medi-Clinic, Morningside, South Africa
Multiple Dose Study of PF-04991532 in Patients With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Diabetes MellitusDiabetes Mellitus, Type 2Glucose Metabolism Disorders
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2011-03-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT01129258
- Locations
- 🇺🇸
Pfizer Investigational Site, San Antonio, Texas, United States
Safety Extension Study Of Tanezumab When Administered By Subcutaneous Injection To Patients With Osteoarthritis
Phase 3
Terminated
- Conditions
- Osteoarthritis
- Interventions
- Biological: Tanezumab
- First Posted Date
- 2010-05-21
- Last Posted Date
- 2021-03-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT01127893
- Locations
- 🇺🇸
Triwest Research Associates, La Mesa, California, United States